Vitamin D loaded into lipid nanoparticles shows insulinotropic effect in INS-1E cells

Elsevier

Available online 2 April 2024, 106758

European Journal of Pharmaceutical SciencesAuthor links open overlay panel, , , , Highlights•

PLGA NPs presented small size and reasonable loading with VitD3 but burst release.

SLNs and NLCs showed larger size but more efficient loading of VitD3.

NLCs showed efficient VitD3 preservation, stability and sustained release.

No cytotoxic effects were observed by treatment with NLCs for up to 72 h.

VitD3 improved cell viability and glucose-stimulated insulin secretion in β cells.

Abstract

Increasing evidence suggests a beneficial role of vitamin D (VitD) supplementation in addressing the widespread VitD deficiency, but currently used VitD3 formulations present low bioavailability and toxicity constrains. Hence, poly(L-lactide-co-glycolide) (PLGA) nanoparticles (NPs), solid-lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) were investigated to circumvent these issues. PLGA NPs prepared by emulsification or nanoprecipitation presented 74 or 200 nm, and association efficiency (AE) of 68 % and 17 %, respectively, and a rapid burst release of VitD3. Both SLN and NLCs presented higher polydispersity and larger NPs size, around 500 nm, which could be reduced to around 200 nm by use of hot high-pressure homogenization in the case of NLCs. VitD3 was efficiently loaded in both SLNs and NLCs with an AE of 82 and 99 %, respectively. While SLNs showed burst release, NLCs allowed a sustained release of VitD3 for nearly one month. Furthermore, NLCs showed high stability with maintenance of VitD3 loading for up to one month at 4 °C and no cytotoxic effects on INS-1E cells up to 72 h. A trending increase (around 30 %) on glucose-dependent insulin secretion was observed by INS-1E cells pre-treated with VitD3. This effect was consistently observed in the free form and after loading on NLCs. Overall, this work contributed to further elucidation on a suitable delivery system for VitD3 and on the effects of this metabolite on β cell function.

Keywords

β cells

cholecalciferol

drug delivery

lipid nanoparticles

supplementation

Data availability

No data was used for the research described in the article.

© 2024 The Author(s). Published by Elsevier B.V.

留言 (0)

沒有登入
gif